Quantcast

Latest Combined small-cell lung carcinoma Stories

2014-08-20 23:02:19

New research report “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the NSCLC Market in top 8 developed nations is predicted to see a 6.6% CAGR through 2020. London, UK (PRWEB) August 20, 2014 The non-small cell lung cancer (NSCLC) market value is expected to increase considerably in the offing...

2014-07-01 16:30:23

Report Stems From National Grassroots Advocacy To Require New Strategic Plans Of Action To Address Deadliest Cancers WASHINGTON, July 1, 2014 /PRNewswire-USNewswire/ -- Today the National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. The report, entitled "Scientific Framework for Small Cell Lung Cancer (SCLC)" was...

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-03-24 23:27:51

Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancer announced today that P2045, the Company's lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). Orphan...

2014-03-05 10:44:37

By eliminating Mcl-1, radiation and chemotherapies could be more effective in treating the most common and deadly of all cancers Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer, which by far...

2014-02-18 23:30:30

Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that it has been selected to present its targeted lung cancer therapy at the 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, also known as the Santa Monica Lung Cancer Meeting. This annual invitation-only meeting gathers the top scientists and clinicians to discuss the latest...

2014-01-09 08:27:02

Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BERGEN, Norway, January 9, 2014 /PRNewswire/ -- Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that preclinical data demonstrating that its lead compound, BGB324 has potential...

Uncommon Antidepressants Could Become Cancer Treatments
2013-09-27 14:23:35

Michael Harper for redOrbit.com - Your Universe Online Two antidepressants that aren’t often prescribed to patients could soon be recommended to serve a completely different purpose; ward off small-cell lung cancer (SCLC). A new bioinformatics study has found these FDA-approved medications are molecularly predisposed to treat SCLC. By investigating the biochemical foundation of these medications, researchers may be able to repurpose the drug without the lengthy and expensive process...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related